Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry
The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field.
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
Tempus AI Inc (NASDAQTEM) shares are trading lower Tuesday after the company reported mixed fourth-quarter financial results. JPMorgan also downgraded the stock following the print.
The stock market experienced a correction on Monday, with the Nasdaq Composite sliding over 200 points. Meanwhile, the Dow inched up 0.08% to 43,461.21, while the Nasdaq dropped 1.2% to 19,286.92. The S&P 500 also declined, slipping 0.5% to 5,983.25. These are the top stocks that gained the attention of retail traders and investors throughout the day:
Tempus shares may be moving higher ahead of its 2024 fiscal-year fourth-quarter earnings report, which is scheduled to be released after the market closes.
Tempus AI (TEM) reports Q4 earnings Monday, expected loss of 20 cents/share, $203.12M in revenues. Stock up 98.80% YTD. Analysts see 13.5% upside with consensus rating of Buy and $59.60 price target.
In the last week, these 13 large-cap stocks were top performers. Are they in your portfolio? HIMS, AUR, APP, SMCI, TEM, DKNG, INTC, MNDY, BROS, CVS, BABA, AAPL, ABNB.
Tempus AI, Inc. (NASDAQTEM) stock is trading higher on Thursday after the company announced a collaboration with the Institute for Follicular Lymphoma Innovation.
